{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.23","upperLimit":"20.30","value":"9.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"OS was measured from the time of treatment initiation until the time of death due to any cause for patients who died, or until the time of last follow-up for patients who survived.","dispersionType":"Full Range","groups":[{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the \"3 times/week, every other week\" schedule.","id":"OG000","title":"Stratum 2"}],"paramType":"MEDIAN","populationDescription":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were enrolled on stratum 2 and received at least one dose of panobinostat were included in the analysis. Per the associated protocol objective, all dose levels on stratum 2 were combined to estimate the OS for this stratum. Two patients who did not start protocol therapy were excluded.","reportingStatus":"POSTED","timeFrame":"From date on treatment until date of death due to any cause or date of last follow-up","title":"Overall Survival (OS) in Stratum 2","type":"SECONDARY","unitOfMeasure":"months"}